|Home | English version | Mappa | Commenti | Sondaggio | Staff | Contattaci||Cerca nel sito|
|Istituto di scienza dell'alimentazione|
Contributo in rivista
Tipo: Articolo in rivista
Titolo: Setting up and exploitation of a nano/technological platform for the evaluation of HMGA1b protein in peripheral blood of cancer patients.
Anno di pubblicazione: 2018
Autori: Capo A, Sepe R, Pellino G, Milone M, Malapelle U, Pellecchia S, Pepe F, Cacciola NA, Manigrasso M, Bruzzaniti S, Sciaudone G, De Palma GD, Galgani M, Selvaggi F, Troncone G, Fusco A, D'Auria S, Pallante P.
Affiliazioni autori: Institute of Food Science, National Research Council (CNR), Via Roma 52, 83100 Avellino, Italy Institute of Experimental Endocrinology and Oncology (IEOS), National Research Council (CNR), Via S. Pansini 5, Naples, Italy Unit of Colorectal Surgery, Department of Medical, Surgical, Neurologic, Metabolic and Ageing Sciences, University of Campania "Luigi Vanvitelli", Piazza Miraglia 2, 80138 Naples, Italy Department of Clinical Medicine and Surgery, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy Department of Public Health, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy Department of Molecular Medicine and Medical Biotechnology, University of Naples "Federico II", Via S. Pansini 5, 80131, Naples, Italy
Abstract: Even if cancer specific biomarkers are present in peripheral blood of cancer patients, it is very difficult to detect them with conventional technology because of their low concentration. A potential cancer biomarker is the HMGA1b protein, whose overexpression is a feature of several human malignant neoplasias. By taking advantage of the surface plasmon resonance (SPR) phenomenon, we realized a specific nano/technology-based assay for cancer detection. More in details, anti-HMGA1b monoclonal antibodies, whose affinity was previously defined by ELISA, were immobilized onto metallic surfaces to develop a direct SPR-based assay. After having analyzed blood samples from colorectal cancer patients and healthy people for the presence of HMGA1b, we observed a 2-fold increase of the HMGA1b levels in the blood of cancer patients with respect to the healthy control people. We conclude that the set-up technology might allow to detect a tumoral mass through the evaluation of HMGA1b protein blood levels.
Lingua abstract: inglese
Stato della pubblicazione: Preprint
|Home | Il CNR | I servizi | News | Eventi | Istituti | Focus|